Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: C/EBPα suppresses the expression of PDGF Receptor β via up regulation of its target gene, 22/April/2014, 6.08 am

Insights into the treatment of human Prostate cancer: Bicalutamide, an Androgen receptor antagonist, increases the expression of tumor suppressor RECK via down regulation of its target gene, 22/April/2014, 5.57 am
April 22, 2014
Insights into lipolytic therapy: Oct-4 promotes lipolysis via down regulation of its target gene, 22/April/2014, 6.49 am
April 22, 2014
Show all

A study from Watson School of Biological Sciences shows that Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β (Pdgfrβ) Signaling. This study was published in the April 10, 2014 Cell by Prof. Dr Scott Lowe, Watson School of Biological Sciences, CSHL, New York; Prof. Dr Carol Prives, Department of Biological Sciences, Columbia University, New York; and others.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that:  Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: C/EBPα suppresses the expression of  PDGF Receptor β (Pdgfrβ) via up regulation of its target gene. Given that tumor suppressor p53 is mutated in about 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 over expressing human cancers can be cured.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Tumor suppressor ARF suppresses the expression of  PDGF Receptor β via up regulation of its target gene, 22/April/2014, 6.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.